Selected for oral presentation at Clinical Trials Mini SymposiumSOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced the presentation of data from the Phase 1 trial of PLN-101095 at the upcoming American Association for Cancer Research (AACR) Annual Meeting taking place in San Diego, California from April 17-22, 2026. The abstrac ...

Clinical Trials - PLN-101095 Phase 1 trial data showed four responders, including one confirmed complete response and three partial responses, out of 10 secondary ICI refractory patients[3] - The accelerated development plan for PLN-101095 includes a Phase 1b indication expansion trial, with first patient enrollment anticipated in Q2 2026[3] - PLN-101095 Phase 1 data accepted for presentation at the AACR Annual Meeting 2026, highlighting the ongoing commitment to advancing clinical research[3] Financial Performance - Net loss for Q4 2025 was $23.6 million, down from $49.7 million in the prior-year quarter, mainly due to the discontinuation of BEACON-IPF and reduced personnel costs[9] - Total operating expenses for Q4 2025 were $23.6 million, compared to $53.3 million in the prior-year quarter[13] - Research and development expenses decreased to $15.6 million in Q4 2025 from $38.8 million in the prior-year quarter, primarily due to the discontinuation of BEACON-IPF[9] - General and administrative expenses decreased to $8.0 million in Q4 2025 from $14.5 million in the prior-year quarter, attributed to lower personnel-related costs from workforce restructuring[9] Assets and Liabilities - As of December 31, 2025, the company had cash, cash equivalents, and short-term investments totaling $192.4 million, expected to fund operations into the second half of 2028[9] - The company’s total assets as of December 31, 2025, were $225.2 million, down from $396.9 million in the prior year[15] - The accumulated deficit increased to $859.4 million as of December 31, 2025, compared to $710.1 million in the prior year[15]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________ FORM 10-K _____________________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39303 _________________ ...

PLN-101095 Phase 1 data showed deep and durable ongoing responses in checkpoint inhibitor refractory solid tumors PLN-101095 accelerated development plan underway with initiation of Phase 1b indication expansion trial SOUTH SAN FRANCISCO, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today provided a corporate update and reported fourth quarter 2025 financial ...

Summary of Pliant Therapeutics FY Conference Call Company Overview - **Company**: Pliant Therapeutics (NasdaqGS:PLRX) - **Focus**: Transitioning from fibrosis to oncology, leveraging an integrin small molecule platform developed over the past 10 years [3][4] Key Points Transition to Oncology - Pliant has shifted its focus from fibrosis to oncology, with a pipeline based on its integrin targeting small molecule platform [3][4] - The most advanced program is **PLN-101095**, a dual v8, v1 integrin small molecule blocker aimed at treating solid tumors, particularly in patients refractory to immune checkpoint inhibitors [4][9] Clinical Data and Pipeline - Initial Phase 1 study of PLN-101095 showed encouraging safety and pharmacokinetic data, with significant biomarker changes observed [4][14] - The drug is administered orally, twice daily, and aims to reduce immune suppression in tumors by blocking TGF- activation [10][11] - A Phase 1b dose expansion study is set to begin in the second quarter of 2026, focusing on combination therapy with Pembrolizumab [15][19] Biomarker Insights - A notable increase in interferon gamma (3-12 fold) was observed in responders during the monotherapy phase, suggesting it may serve as a predictive biomarker for treatment response [14][28][29] - The average tumor size reduction in responders was 71%, with an overall response rate of 40% in secondary refractory patients [27] Future Development Plans - Plans to initiate a Phase 1b study with a focus on specific tumor types, including non-small cell lung cancer and renal cell carcinoma, based on v8 expression profiles [16][17][19] - Continuous evaluation of external opportunities for in-licensing or acquisition of complementary assets [7][36] Financial Position - As of the third quarter, Pliant reported approximately **$211 million** in cash, with a burn rate significantly decreased, providing a runway into the second half of 2028 [40][41] - The company has restructured to maintain development capabilities while reducing operational costs [42][43] Competitive Landscape - Pliant's approach is differentiated from competitors, as it utilizes a small molecule that targets both v1 and v8 integrins, unlike other antibody-based therapies in development [21][22] - The company is monitoring other TGF- targeted programs to inform its indication selection [23][24] Additional Insights - The targeted drug delivery platform using siRNA is being developed internally, with a focus on selective delivery to specific cell types [5][37] - The company aims to provide updates on clinical execution and data from non-human primate studies later in the year [35][36] This summary encapsulates the key points discussed during the conference call, highlighting Pliant Therapeutics' strategic transition, clinical developments, financial health, and competitive positioning in the oncology space.

Group 1 - Mosiv Capital is a proprietary investment firm that focuses on generating absolute returns uncorrelated to macroeconomic conditions, rooted in the principles of Benjamin Graham and Warren Buffett [2] - The firm targets small- and mid-cap equities, seeking severely mispriced assets that are overlooked by large institutional investors [2] - Mosiv Capital employs a disciplined approach to investing, utilizing options to manage risk and extract structural returns through contrarian investing and event-driven arbitrage [2] Group 2 - The firm operates with zero leverage and systematically underwrites cash-secured puts, ensuring that every option trade is fully backed by cash [2] - Mosiv Capital's strategy includes a focus on dislocation and niche markets, as well as tail-risk underwriting to capitalize on high market volatility [2]

SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced its participation in the Oppenheimer 36th Annual Healthcare Life Sciences Conference being held in a virtual format February 25-26, 2026. Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer and Keith Cummings, M.D., Chief Financial Officer, will participate in a f ...

Core Viewpoint - Pliant Therapeutics is gaining attention due to promising interim trial results for its cancer therapy, PLN-101095, despite a significant decline in its stock price [1][8]. Group 1: Trial Results - Pliant Therapeutics released interim data from its Phase 1 dose escalation trial of PLN-101095, which was evaluated in combination with Merck's Keytruda for patients with immune checkpoint inhibitor-refractory advanced or metastatic solid tumors [2]. - In a heavily pretreated patient population, PLN-101095 demonstrated antitumor activity, with four responders identified, including one confirmed complete response and three partial responses [3][4]. - Clinical responses were observed in various cancer types, including cholangiocarcinoma, melanoma, head and neck squamous cell carcinoma, and non-small cell lung cancer [4]. Group 2: Patient Outcomes - The median time on treatment for patients was 15 months, with 60% of secondary refractory patients showing stable disease or tumor reduction [5]. - All responding patients exhibited significant increases in plasma interferon gamma (IFN-γ) levels after a 14-day monotherapy run-in period, while non-responders did not show meaningful increases [5]. Group 3: Safety and Future Plans - PLN-101095 was generally well tolerated across all tested doses and exhibited a dose-dependent pharmacokinetic profile [6]. - Pliant plans to accelerate the development of PLN-101095 with a Phase 1b indication expansion trial set to begin in 2026, focusing on non-small cell lung cancer and other tumor types [7].

Summary of Pliant Therapeutics FY Conference Call Company Overview - **Company**: Pliant Therapeutics (NasdaqGS:PLRX) - **Event**: 37th Annual Piper Sandler Healthcare Conference - **Date**: December 04, 2025 Key Highlights - **Phase 1 Study Results**: - The study showed a median treatment duration of **15 months** with **four responders**, including **one complete responder** in heavily pretreated patients [2][3] - Notable case: A cholangiocarcinoma patient achieved a complete response after failing multiple therapies, including chemotherapy and radiotherapy [3] - **Interferon Gamma Response**: - The interferon gamma signal was identified as a significant predictor of response, observed after **14 days** of monotherapy with the drug **10-10-95** [5] - This signal was statistically significant compared to baseline and was also seen preclinically in animal models [5] - **Safety Profile**: - The drug was well tolerated, with the most common adverse event being mild to moderate rash, leading to only one discontinuation due to rash [5][6] - **Program Advancement**: - The company plans to move forward with part two of the study, focusing on **non-small cell lung carcinoma** and other tumor types [10] - The study will continue to explore the interferon gamma signal and other biomarkers [10] - **Future Data Timeline**: - Anticipated data from the ongoing studies may be available in **2027**, depending on cohort size and study design [15][33] Strategic Direction - **Oncology Focus**: - Pliant remains committed to its integrin platform, with a focus on oncology as the lead asset while also exploring earlier-stage programs [22][24] - The company is open to opportunistic acquisitions to enhance its pipeline [25][41] - **Competitive Landscape**: - The oncology space is competitive, particularly for ICI refractory patients, with current options showing progression-free survival (PFS) of **3 to 5 months** [26][28] - Key competitors include companies focusing on bispecifics and AbbVie, which has a similar mechanism of action [28][29] - **Platform Capabilities**: - Pliant is developing a siRNA delivery platform targeting specific cell types, with potential indications expected to be disclosed in **2026** [24][31] Financial Position - **Cash Reserves**: - The company has sufficient cash to support operations through **2028**, providing flexibility in resource allocation [37][39] Additional Insights - **Team and Execution**: - Pliant has maintained its core development capabilities and is looking to enhance expertise in clinical oncology and regulatory affairs [51] - **Pipeline Development**: - The company has several small molecules ready for development in various indications, with a focus on oncology and chronic diseases [31][32] This summary encapsulates the key points discussed during the conference call, highlighting Pliant Therapeutics' current status, future plans, and competitive positioning in the biotechnology sector.

Developing Novel Integrin-Based Therapeutics DECEMBER 2025 © 2025 PLIANT THERAPEUTICS Disclaimers This presentation has been prepared by Pliant Therapeutics, Inc. ("we," "us," "our," "Pliant" or the "Company"). The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this presentation unless stated otherwise, and this presentation shall not under any circumstances create an implication that th ...